Box Warning News Today

also breaking this morning, signs that the labor market, which has been stunningly strong for so long is now cooling. fed watchers and wall street very warily awaiting these numbers. ill talk to acting labor secretary julie su for her take on the numbers and the strength of the u.s. economy. and later, more heat for an already weather-weary nation. over a dozen dead nationwide from the high temperatures. >> i have asthma, so the air quality is really hard on my lungs, and then with t...

August. >> alzheimers threw us for a loop, this drug has thrown us a lifeline. >> that was nbcs kate snow reporting. back with us now, dr. vin gupta. doctor, this drugs approval is encouraging news for people with alzheimers and their families, but it isnt a cure, right? it just slows it down. so how much of a difference will people see? >> ana, thats the critical question. this is a milestone. this is a fist step towards new therapeutics to the point that kate made in her segment here. this i...

​​​​​​​We have decided that 2023 will be a year of new adventures for us.  We are dipping our toes into the world of dog shows (our gorgeous poodle puppy is now past five months old and...

/PRNewswire/ -- On February 22, 2022, the personal injury law firm of Cunningham Bounds, LLC obtained a $35 million jury verdict for the family of a man who...

/PRNewswire/ -- On February 22, 2022, the personal injury law firm of Cunningham Bounds, LLC obtained a $35 million jury verdict for the family of a man who...

Noted antidepressant researcher, Michael Hengartner, summarizes the latest research on the use of antidepressants in children and adolescents.

Radius Health, Inc.: First Quarter 2021 Results Total net revenue: $56 million vs. $48 million in Q1, 2020, +17% year-over-year TYMLOS Significant operating leverage improvement: Q1, 2021 EPS: ($0.34) vs. ($0.81) in Q1, 2020 Reiterating $250 million for full year 2021 net revenue guidance for the U.S. TYMLOS product Humana added TYMLOS to the formularies of its Medicare Advantage Plans on May 1, 2021 Abaloparatide pivotal trials: ATOM (male) and wearABLe (TD) on schedule for 2H, 2021 readouts C...